Learn from experts in the field on contemporary diagnosis and management of C. diff infection. Topics include new diagnostic strategies and best treatment plans for our patients.
SPEAKERS
Dr. Ciaran P. Kelly has been involved in patient care and research in Clostridium difficile infection for more than 30 years. He leads NIH-funded research programs on the diagnosis of C. difficile infection and on potential C. difficile vaccines and other immune-based treatments. Dr. Kelly has served as a committee member of the NIH Center for Scientific Review, as well as FDA, CDC, and NIH committees on C. difficile infection. Dr. Kelly is the author of more than 250 original articles, clinical and basic research book chapters, and invited reviews appearing in such journals as Gastroenterology, Journal of Biological Chemistry, Journal of Clinical Investigation, New England Journal of Medicine, and Lancet.
Relevant Financial Relationship Disclosure
-
Artugen Therapeutics, Facile Therapeutics, Ferring Pharmaceuticals, Finch Therapeutics, Matrivax, Merck, Seres Therapeutics, Vedanta Biosciences: consultant and advisor
-
Merck: contracted research
-
First Light Biosciences: stock options
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated.
Kevin W. Garey, Pharm.D., M.S., FASHP, is Professor and Chair of the Department of Pharmacy Practice and Translational Research at the University of Houston College of Pharmacy in Houston, Texas. Dr. Garey is also Adjunct Professor at the University of Texas School of Public Health and Clinical Specialist and Researcher at Baylor St. Luke’s Medical Center in Houston. He is a member of the Infectious Diseases Society of American (IDSA) Standards and Practice Guidelines Committee and is a member of the IDSA-Society of Healthcare Epidemiology of America (SHEA) practice guidelines for C. difficile infection (CDI). Dr. Garey's research, supported by the National Institute of Health, the Centers for Disease Control and Prevention, and the pharmaceutical industry, involves clinical and translational research in healthcare-associated infections including post-surgical infections, candidemia, and CDI.
Relevant Financial Relationship Disclosure
- Paratek Pharm, Acurx Pharmaceuticals, Summit Pharmaceuticals: research grants
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated.
All other persons in control of content do not have any relevant financial relationships with an ineligible company.
This podcast is provided by ASHP and supported by an educational grant from Merck.